Urbach Tanya Durkee 4

What Happened

• Tanya Durkee, a director of CytoDyn Inc. (CYDY), was granted an equity award reported as a derivative acquisition of 574,385 shares on March 20, 2026. The filing shows an acquisition price of $0.00 per share (derivative security), i.e., no cash paid at grant.

Key Details

• Transaction date: 2026-03-20; filing date (Form 4): 2026-03-24 (filed within the required two business days).
• Transaction type/code: A = Award/Grant (derivative security).
• Shares/units granted: 574,385 (reported at $0.00 per share in the filing).
• Ownership after transaction: Not specified in the public Form 4 excerpt provided.
• Notable footnotes:
  • F1: Grant approved by the Compensation Committee on March 20, 2026; annual grant under the Issuer’s 2012 Equity Incentive Plan (shares reserved under the plan).
  • F2: The award is structured as a stock option that will vest in approximately 12 equal monthly installments from April 2026 through March 2027.
• Timeliness: Filing appears timely (not marked late).

Context

• This was an equity award (derivative/option) to a director as part of routine compensation—common for board members and consistent with the company’s stated annual grant practice. Such awards are standard compensation and do not, by themselves, indicate buy/sell sentiment; vesting schedule means economic benefit is realized over the coming year.